Endocytic Ark/Prk kinases play a critical role in adriamycin resistance in both yeast and mammalian cells

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11932-11937

  Takahashi, Tsutomu ^a   Furuchi, Takemitsu ^a,b   Naganuma, Akira ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DOXORUBICIN; FUNGAL PROTEIN; PROTEIN AKL1; PROTEIN ARK1; PROTEIN KINASE C; PROTEIN PAN1; PROTEIN PRK1; PROTEIN SLA1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION; DRUG BLOOD LEVEL; DRUG MECHANISM; ENDOCYTOSIS; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SACCHAROMYCES CEREVISIAE; YEAST CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; DNA PRIMERS; DOXORUBICIN; DRUG RESISTANCE; ENDOCYTOSIS; HUMANS; ISOQUINOLINES; KIDNEY; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 33846222366     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3220     Document Type: Article

References (45)

1. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974;33:19-27.
2. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
3. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 Suppl 4:1-7.
4. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994;47:223-58.
5. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987;262:505-8.
6. Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts T, Smit JJ, Borst P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res 1990;50:1779-85.
7. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998;20:931-40.
8. Boquete AL, Vargas Roig L, Lopez GA, et al. Differential anthracycline sensitivity in two related human colon carcinoma cell lines expressing similar levels of P-glycoprotein. Cancer Lett 2001;165:111-6.
9. Kaye SB. Clinical drug resistance: the role of factors other than P-glycoprotein. Am J Med 1995;99:40-4S.
10. Furuchi T, Nitta K, Takahashi T, Naganuma A. Overexpression of Ssl2p confers resistance to Adriamycin and actinomycin D in Saccharomyces cerevisiae. Biochem Biophys Res Commun 2004;314:844-8.
11. Furuchi T, Takahashi T, Tanaka S, Nitta K, Naganuma A. Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of Adriamycin. Nucleic Acids Res 2004;32:2578-85.
12. Takahashi T, Furuchi T, Naganuma A. A novel role for Bsd2 in the resistance of yeast to Adriamycin. J Cell Physiol 2005;202:100-4.
13. Smythe E, Ayscough KK. The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin skeleton. EMBO Rep 2003;4:246-51.
14. Zeng G, Cai M. Regulation of the actin cytoskeleton organization in yeast by a novel serine/threonine kinase Prk1p. J Cell Biol 1999;144:71-82.
15. Zeng G, Yu X, Cai M. Regulation of yeast actin cytoskeleton-regulatory complex Pan1p/Sla1p/End3p by serine/threonine kinase Prk1p. Mol Biol Cell 2001;12:3759-72.
16. Conner SD, Schmid SL. Differential requirements for AP-2 in clathrin-mediated endocytosis. J Cell Biol 2003;162:773-80.
17. Naganuma A, Miura N, Kaneko S, et al. GFAT as a target molecule of methylmercury toxicity in Saccharomyces cerevisiae. FASEB J 2000;14:968-72.
18. Hwang GW, Sasaki D, Naganuma A. Overexpression of Rad23 confers resistance to methylmercury in Saccharomyces cerevisiae via inhibition of the degradation of ubiquitinated proteins. Mol Pharmacol 2005;68:1074-8.
19. Hwang GW, Furuchi T, Naganuma A. A ubiquitin-proteasome system is responsible for the protection of yeast and human cells against methylmercury. FASEB J 2002;16:709-11.
20. Cope MJ, Yang S, Shang C, Drubin DG. Novel protein kinases Ark1p and Prk1p associate with and regulate the cortical actin cytoskeleton in budding yeast. J Cell Biol 1999;144:1203-18.
21. Tang HY, Munn A, Cai M. EH domain proteins Pan1p and End3p are components of a complex that plays a dual role in organization of the cortical actin cytoskeleton and endocytosis in Saccharomyces cerevisiae. Mol Cell Biol 1997;17:4294-304.
22. Warren DT, Andrews PD, Gourlay CW, Ayscough KR. Sla1p couples the yeast endocytic machinery to proteins regulating actin dynamics. J Cell Sci 2002;115:1703-15.
23. Conner SD, Schmid SL. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J Cell Biol 2002;156:921-9.
24. Ricotta D, Conner SD, Schmid SL, von Figura K, Honing S. Phosphorylation of the AP2μ subunit by AAK1 mediates high affinity binding to membrane protein sorting signals. J Cell Biol 2002;156:791-5.
25. Korolchuk VI, Banting G. CK2 and GAK/auxilin2 are major protein kinases in clathrin-coated vesicles. Traffic 2002;3:428-39.
26. Umeda A, Meyerholz A, Ungewickell E. Identification of the universal cofactor (auxilin 2) in clathrin coat dissociation. Eur J Cell Biol 2000;79:336-42.
27. Watson HA, Cope MJ, Groen AC, Drubin DG, Wendland B. In vivo role for actin-regulating kinases in endocytosis and yeast epsin phosphorylation. Mol Biol Cell 2001;12:3668-79.
28. Henry KR, D'Hondt K, Chang JS, et al. The actin-regulating kinase Prk1p negatively regulates Scd5p, a suppressor of clathrin deficiency, in actin organization and endocytosis. Curr Biol 2003;13:1564-9.
29. Gourlay CW, Dewar H, Warren DT, Costa R, Satish N, Ayscough KR. An interaction between Sla1p and Sla2p plays a role in regulating actin dynamics and endocytosis in budding yeast. J Cell Sci 2003;116:2551-64.
30. Ayscough KR, Eby JJ, Lila T, Dewar H, Kozminski KG, Drubin DG. Sla1p is a functionally modular component of the yeast cortical actin cytoskeleton required for correct localization of both Rho1p-GTPase and Sla2p, a protein with talin homology. Mol Biol Cell 1999;10:1061-75.
31. Mochida J, Yamamoto T, Fujimura-Kamada K, Tanaka K. The novel adaptor protein, Mti1p, and Vrp1p, a homolog of Wiskott-Aldrich syndrome protein-interacting protein (WIP), may antagonistically regulate type I myosins in Saccharomyces cerevisiae. Genetics 2002;160:923-34.
32. Breton AM, Schaeffer J, Aigle M. The yeast Rvs161 and Rvs167 proteins are involved in secretory vesicles targeting the plasma membrane and in cell integrity. Yeast 2001;18:1053-68.
33. Babst M, Odorizzi G, Estepa EJ, Emr SD. Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 2000;1:248-58.
34. Piper RC, Cooper AA, Yang H, Stevens TH. VPS27 controls vacuolar and endocytic traffic through a prevacuolar compartment in Saccharomyces cerevisiae. J Cell Biol 1995;131:603-17.
35. Kolaczkowski M, van der Rest M, Cybularz-Kolaczkowska A, Soumillion JP, Konings WN, Goffeau A. Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. J Biol Chem 1996;271:31543-8.
36. Egner R, Kuchler K. The yeast multidrug transporter Pdr5 of the plasma membrane is ubiquitinated prior to endocytosis and degradation in the vacuole. FEBS Lett 1996;378:177-81.
37. Egner R, Mahe Y, Pandjaitan R, Kuchler K. Endocytosis and vacuolar degradation of the plasma membrane-localized Pdr5 ATP-binding cassette multidrug transporter in Saccharomyces cerevisiae. Mol Cell Biol 1995;15:5879-87.
38. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT, Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265:10073-80.
39. Ross DD, Gao Y, Yang W, Leszyk J, Shively J, Doyle LA. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen. Cancer Res 1997;57:5460-4.
40. Tokes ZA, Rogers KE, Rembaum A. Synthesis of Adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci U S A 1982;79:2026-30,
41. Triton TR, Yee G. The anticancer agent Adriamycin can be actively cytotoxic without entering cells. Science 1982;217:248-50.
42. Tapiero H, Mishal Z, Wioland M, Silber A, Fourcade A, Zwingelstein G. Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin. Anticancer Res 1986;6:649-52.
43. Cheng ZJ, Deep Singh R, Marks DL, Pagano RE. Membrane microdomains, caveolae, and caveolar endocytosis of sphingolipids (review). Mol Membr Biol 2006;23:101-10.
44. Molinari A, Calcabrini A, Crateri P, Arancia G. Interaction of anthracyclinic antibiotics with cytoskeletal components of cultured carcinoma cells (CG5). Exp Mol Pathol 1990;53:11-33.
45. DalleDonne I, Milzani A, Contini P, Bernardini G, Colombo R. Interaction of cardiac α-actinin and actin in the presence of doxorubicin. Exp Mol Pathol 1992;55:229-38.